Psilocybin Restores Social Behavior in OCD Mouse Model: Prefrontal Circuit Insights

Psilocybin Restores Social Novelty in an OCD Mouse Model

Psilocybin, a serotonergic psychedelic, has been shown to restore social novelty investigation in male SAPAP3 knockout mice—a well-validated animal model for obsessive-compulsive disorder (OCD)—according to a study published on September 17, 2026 (OpenAlex W7213460784). In this experiment, male and female SAPAP3 knockout (KO) mice and their wild-type littermates were administered a single 1 mg/kg intraperitoneal dose of psilocybin. Seven days later, social behavior was assessed using the three-chamber social interaction test. The results demonstrated that psilocybin produced a male-specific, lasting restoration of novel-mouse-directed investigation, a behavioral measure of social recognition and novelty seeking. Female KO mice did not show similar improvements, underscoring a sex-specific effect.

Mechanistic Insights: Infralimbic Prefrontal Cortex Activation

The study identified increased neural activation in the medial prefrontal cortex and hippocampus following psilocybin administration, as measured by c-Fos immunohistochemistry. Critically, only infralimbic prefrontal cortex (IL-PFC) activation correlated with improved social novelty behavior in male SAPAP3 KO mice. This finding suggests that psilocybin’s therapeutic effect on social cognition may be mediated by plasticity-related mechanisms in the IL-PFC, rather than broader limbic or striatal circuits. Notably, c-Fos expression in the nucleus accumbens, basolateral amygdala, and dorsal striatum was unchanged, indicating a domain-specific circuit engagement. This mechanistic specificity is a key insight, as most competing literature has not differentiated prefrontal subregion involvement in psychedelic-induced behavioral rescue.

Context: Social Dysfunction in OCD and Unmet Needs

Social dysfunction is a significant but under-recognized burden for individuals with OCD and related neuropsychiatric disorders. Current pharmacological treatments for OCD, such as selective serotonin reuptake inhibitors (SSRIs), do not specifically address social cognitive deficits. The SAPAP3 KO mouse is a widely used model for compulsive-like behaviors and has recently gained attention for its social abnormalities, which parallel those seen in human OCD. By demonstrating that psilocybin can selectively restore social novelty investigation in this model, the study provides a stronger mechanistic rationale for exploring psychedelics as interventions for social symptoms—not just compulsive behaviors—in OCD and possibly other disorders with overlapping social impairments.

• Translational Value: The enduring effect (measured one week post-administration) suggests potential for long-lasting benefit, an important consideration for clinical trial design.
• Domain Specificity: The lack of effect in other brain regions and the male-specific response highlight the need for stratified clinical approaches and careful patient selection in future studies.

Policy and Research Implications

These preclinical findings strengthen the case for clinical trials targeting social dysfunction in OCD and related disorders. Regulatory agencies such as the U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA) have not yet approved any pharmacological treatments specifically for social cognitive deficits in OCD. The study’s identification of a defined neural substrate (IL-PFC) for psilocybin’s effect could inform biomarker selection and mechanistic endpoints in early-phase human trials. Furthermore, the sex-specific findings highlight the importance of including sex as a biological variable in future research, a requirement increasingly emphasized by funding agencies and ethics boards.

One non-obvious implication is that preclinical studies should incorporate circuit-level readouts and behavioral endpoints relevant to social cognition, rather than focusing solely on compulsive or repetitive behaviors. This approach may accelerate the translation of psychedelics for broader neuropsychiatric indications beyond classic symptom domains.

Risks, Unknowns, and Limitations

While the results are promising, several limitations must be considered. The study is preclinical, and behavioral rescue in mice does not guarantee efficacy or safety in humans. The male-specific effect raises questions about underlying sex differences in serotonergic signaling or circuit plasticity, which are not yet understood. Additionally, the dosing regimen (single 1 mg/kg injection) and route (intraperitoneal) do not directly translate to clinical practice. The enduring effect observed at seven days post-administration is encouraging, but long-term safety and potential for adverse effects—including the risk of exacerbating compulsive or psychotic symptoms—remain unknown in both animal models and humans.

Finally, the study did not assess the impact of psilocybin on other OCD-relevant behaviors, nor did it explore possible off-target effects or abuse liability. These gaps highlight the need for comprehensive, multi-domain preclinical assessments before advancing to human trials.

Looking Ahead: Next Steps for Translational Research

The demonstration that psilocybin can restore social novelty investigation via infralimbic prefrontal cortex engagement in a genetic OCD model marks a significant advance in the mechanistic understanding of psychedelic effects. The next steps include replication in additional models, exploration of sex differences, and integration of circuit-specific biomarkers into early-phase clinical trials. Given the lack of existing treatments for social dysfunction in OCD, these findings support the prioritization of translational research programs and may inform regulatory guidance on trial design for novel interventions targeting social cognition in neuropsychiatric disorders.

How we research: This article was written and reviewed by Dr. Alex R. Bennett, PhD (Neuroscience), with direct reference to the original study (OpenAlex W7213460784) and current regulatory guidance from the FDA and EMA. Reviewed on 2026-09-18.